Sentences with phrase «new vaccine technologies»

5) Explore new vaccine technologies — Longer term, we need to evaluate new ways to vaccinate wild carnivores for distemper, in situations wherein use of an injectable vaccine is not feasible by hand or by dart.

BRUSSELS — CureVac, a company based in Tübingen, Germany, that develops RNA - based vaccines and therapies, has won a $ 2 million prize awarded by the European Commission to stimulate new vaccine technologies that might help the developing world.

Not exact matches

Today his company is developing a new cancer vaccine technology that teaches immune cells how to recognize and remove tumor cells.

This technology could help researchers rapidly generate new peptide drugs to test on a variety of diseases, and it also raises the possibility of easily producing customized cancer vaccines for individual patients.

To fund the new approach to the work, tenOever contacted the Army Research Office, which sponsors new technology for vaccine development.

To create a new dengue virus vaccine, Stefan Metz, Shaomin Tian in the laboratories of Aravinda de Silva, Chris Luft and Joe DeSimone at the University of Carolina, Chapel Hill, USA designed nanoparticles of various shapes and sizes using Particle Replication in Non-wetting Template (PRINT) technology.

Moderna is a clinical stage pioneer of messenger RNA (mRNA) therapeutics and vaccines, an entirely new drug technology that directs the body's cells to produce intracellular or secreted proteins.

In November 2012, the company also showed, along with scientists from the Friedrich Loeffler Institute, that the technology could lead to a new generation of flu vaccines.

The majority of new drugs and vaccines are developed within the private sector and they are developed as commercial goods so there is a lack of a public mechanism to advance R&D of new technologies.

My role is to provide professional scientific secretarial support to 13 different PHLS expert advisory committees, covering wide - ranging areas from vaccines and immunisation, virology, and new technology to mycobacteria and systemic and respiratory viruses.

The ability to design new protein nanostructures could have useful implications in targeted delivery of drugs, in vaccine development and in plasmonics — manipulating electromagnetic signals to guide light diffraction for information technologies, energy production or other uses.

IDMIT will contribute 1) To the development and validation of assays based on flow cytometry and mass cytometry for the evaluation of immune responses in humans and animal models; these tools will be particularly relevant for the identification of signatures of vaccine efficacy; 2) To the animal model platform, in particularly by providing access to NHP models and to new technologies for in vivo imaging infections and host responses; 3) To networking activities, in particular by organising a workshop on in vivo imaging.

iBET's infrastructure comprises 16 laboratories fully equipped with state - of - the - art technology (70 m2 each), including a BSL2 laboratory for working with viruses; a GMP Analytical Services Unit certified by the INFARMED (the Portuguese medicines authority, EMA Portuguese branch) and by DGAV (the Portuguese veterinary authority) for quality control and batch release of human and veterinary pharmaceuticals, biopharmaceuticals as well as experimental new drugs; a GMP Mass - Spectroscopy Unit that provides state - of - the - art MS services to the scientific community and Industry; a 2600 m2 bio-pilot plant supporting production and purification of proteins ATMPs and vaccines from bench top to 300 L scale and privileged access to GeniBET Biopharmaceuticals, an iBET spin - off producing ATMPs under cGMP certification for phase I / II / III clinical trials.

We use our mammalian expression technologies to create panels of recombinant pathogen proteins that are then used to identify new subunit vaccine targets for infectious diseases.

The program will be packed with papers on biochromatography, downstream processing, QbD, monoclonal antibodies, plasmids, enzymes, vaccines, viral vectors for gene delivery, VLPs, and other biopharmaceuticals, chiral molecules, SFC, fine chemicals, peptides, proteins, oligonucleotides, APIs, natural products, batch, multi-column and continuous SMB processes, column technology and equipment, monoliths, new and improved stationary phases, membrane chromatography, regulatory aspects, and more!

Synthetic Genomics (SGI) and the J. Craig Venter Institute (JCVI) have formed a new company, Synthetic Genomics Vaccines (SGVI), to develop next - generation vaccines based on synthetic genome tecVaccines (SGVI), to develop next - generation vaccines based on synthetic genome tecvaccines based on synthetic genome technology.

April 7, 2018 - The University of Florida, along with partners in the United States and Japan, received a $ 3.2 million grant from the Global Health Innovative Technology Fund to continue the development of a new malaria vaccine.

«This is a straightforward study of the use of two established vaccine technologies in an attempt to design and test new Zika vaccines.

Massachusetts Institute of Technology (MIT) researchers have discovered a new way to model malaria using stem cells in a petri dish, which will allow them to test potential antimalarial drugs and vaccines.

The Ertl laboratory has pioneered numerous patented technologies to create new vaccines.

Much of the laboratory's efforts on developing a new preventative vaccine for rabies — a disease that retains a disastrous presence in places across the globe — have yielded useful technologies that the Ertl laboratory is applying to combating other viruses.

For his part, Shusteff noted that the malarial vaccine purification system technology had been sitting in mothballs for three to four years — and has been given new life through the IDF.

Scientific programs include: human genomic sequencing and analysis, synthetic genomics and exploration of new vaccines using this technology, and environmental and single cell genomics to explore the vast unseen world of microbes living in the human body, the ocean, soil and air.

Moving the Needle provides quarterly updates from PATH's Center for Vaccine Innovation and Access (CVIA) on our vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technoVaccine Innovation and Access (CVIA) on our vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technovaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technovaccine manufacturers, and evaluating new adjuvants and other novel vaccine technovaccine technologies.

Recent research focuses on vaccine development in accordance with current ICH guidelines (QbD and PAT) and the development of new platform - technology for vaccines.

The technology behind the new Ebola vaccine was devised nearly a decade ago by Peter Halfmann, a research scientist in Kawaoka's lab who is also an expert on the Ebola virus.

In the last few years, advances in both vaccine technology and our understanding of the workings of the immune system have lead to a new three - year protocol for some vaccines, such as distemper and parvo.

This is a new treatment that uses vaccine technology to eliminate one of the main mediators of itch sensation.

While the technology is new to flu vaccine production, it is used to make vaccines that have been approved by the FDA to prevent other infectious diseases.

«The new technology offers the potential for faster start - up of the vaccine manufacturing process in the event of a pandemic, because it is not dependent on an egg supply or on availability of the influenza virus.»